29,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
15 °P sammeln
  • Broschiertes Buch

The prevalence of Crohn's disease (CD), a chronic and life-threatening inflammatory bowel disease (IBD), is steadily increasing worldwide. A shift to personalized medicine is required because CD is a very heterogeneous disease that poses ongoing challenges in prognosis and treatment selection. The crucial and quickly developing field of disease prognosis receives a significant amount of attention. In addition to examining markers for predicting disease course and the growing potential of proteomics for forecasting disease activity and treatment response, the book goes beyond conventional…mehr

Produktbeschreibung
The prevalence of Crohn's disease (CD), a chronic and life-threatening inflammatory bowel disease (IBD), is steadily increasing worldwide. A shift to personalized medicine is required because CD is a very heterogeneous disease that poses ongoing challenges in prognosis and treatment selection. The crucial and quickly developing field of disease prognosis receives a significant amount of attention. In addition to examining markers for predicting disease course and the growing potential of proteomics for forecasting disease activity and treatment response, the book goes beyond conventional evaluations to emphasize the clinical significance of biomarkers in CD. Finally, the book offers an exhaustive review of potential factors associated with the progression of CD and the current medical treatments guiding toward effective, personalized patient management.
Autorenporträt
Dalia Medhat, professor of medical biochemistry at the National Research Centre-Egypt, is an expert in medical research and translational science. Her work spans cancer biology, stem cell therapy, nanomedicine, and using natural compounds to treat diabetes, neurodegenerative diseases, and liver disorders.